Enterprise Europe Network

Irish Biotech company has developed the world's first germ free chicken eggs & birds in commercial quantities for pharmaceutical industry, seeking distribution agreements

Country of origin:
Country: 
IRELAND
Opportunity:
External Id: 
BOIE20190912003
Published
12/09/2019
Last update
25/10/2019
Expiration date
25/10/2020

Keywords

Partner keyword: 
Pharmaceutical Products / Drugs
Microbiology
Microbiology
Manufacture of pharmaceutical preparations
EXPRESS YOUR INTEREST

Summary

Summary: 
Irish company in the biotechnology space has developed the process of producing germ free chicken eggs and germ free birds in commercial quantities for pharmaceutical industry seeking distribution agreements opportunities from Europe, USA and Brazil.

Description

Description: 

An irish innovation-based biotechnology company, providing germ free eggs seeking a distribution contract to supply companies who make vaccinations in the pharmaceutical industry

The company has developed a process of producing germ free chicken eggs and germ free birds in commercial quantities for use primarily in the pharmaceutical industry.

Germ-Free eggs are preferred as currently 10-20% of eggs produced from normal or specific pathogen free laying flocks are infected with bacteria and viruses on the inside provides many advantages over current sources of eggs.

The company can also offer large scale production of recombinant proteins to good manufacturing practice standard using an avian transgenic platform compliant with usda memo 800.65, nace code 2120 manufacture of pharmaceutical preparations and european pharmacopoeia requirements.

Applications of germ free eggs/cells/tissues

1. Conventional (prophylactic) vaccines
- whole egg
- primary cell cultures
- modified vaccinia ankarabased (e.g. bioterrorism vaccines)
- other pox virus-based vaccines

2. Therapeutic vaccines
- cancer vaccines (e.g. modified vaccine ankarabased-based cervical (human papillomavirus ) vaccine, lung (cell lung cancer) vaccines)
- infections agents (e.g. human immunodeficiency viruses )

3. Pharmaceutical (e.g. hyaluronic acid, phospholipids)
The company has received patent protection in both europe and the US for the process by which it produces germ free eggs and further patent approvals are pending.

The company is interested in finding opportunities to grow the business on world markets, and to provide distribution agreements to locate a distribution centre in a local market (either Europe, USA or Brazil) to help deliver a unique product.

Advantages & innovations

Cooperation plus value: 
- A safe, biosecure, large scale, flexible and cost-effective biomanufacturing platform for the production of vaccines and therapeutic proteins. - No contamination from eggs of batches of vaccines / therapeutic proteins / antisera. - Leads to substantial cost saving and greater continuity of supply of finished product - Removes risk of egg-derived contamination of pharmaceutical / vaccine manufacturing facilities

Technical Specification or Expertise Sought

Cooperation sought: 
Seeking distribution agreements to locate a distribution centre in a local market to help deliver germ free egg production.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
The company is interested in finding opportunities to grow the business on world markets, and to provide distribution agreemnts to provide germ free eggs to pharmaceutical companies producing vaccines.

Type and size

Cooperation task: 
>500 MNE,251-500,>500